The white paper presents how Genialis™ krasID predicts treatment responses in KRAS-mutated cancers. By combining RNA phenomarkers with explainable AI, krasID captures the active biology of tumors to deliver customizable and interpretable predictors tailored to specific KRAS inhibitors. Case studies from preclinical models, pan-cancer analyses, and real-world sotorasib-treated patients highlight its ability to predict response, forecast durability, and uncover resistance mechanisms, supporting more effective trials and personalized treatment strategies.

Content overview:

• KRAS inhibitors need RNA-based phenomarkers
• RNA phenomarkers and explainable AI make Genialis™ krasID a powerful tool for KRAS inhibitors.
• krasID as a platform for compound-specific KRASi phenomarkers
• Case studies: Validating krasID in preclinical proof of concept, pan-cancer analysis and real-world patient study
• Starting a collaboration: Discover the process of training a new predictor and technical implementation of our biomarker products

Enhance your approach to targeted cancer therapies. Download the white paper to explore how Genialis krasID leverages RNA-based predictions to refine treatment strategies for KRAS-mutated cancers. Gain advanced insights that can help you optimize patient outcomes in your research and clinical trials!